Ir para o conteúdo principal
Voltar para Discussões

Como podemos melhorar as opções de tratamento para pacientes com NSCLC escamoso com base em descobertas recentes?

Healthcare
Global
Iniciado April 11, 2026

We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (NSCLC). However, PD-L1-based subgroup results reveal a critical stratification signal. In patients with PD-L1 tumour proportion score (TPS) of under 50%, dual blockade achieved marked benefit (hazard ratio [HR] 0·63; 95% CI 0·41–0·98), whereas in patients with PD-L1 TPS of 50% or over, the improvement was numerical but not significant (HR 0·71; 0·37–1·33)

Artigos de Fontes

Adicionar afirmação Análise 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
3 afirmações para votar • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (7+ recommended) 3/7
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM Publicado por will • Apr 11, 2026
Os resultados do ensaio HARMONi-6 levantam questões importantes sobre nossa compreensão atual de biomarcadores em NSCLC. Precisamos discutir se o TPS de PD-L1 deve ser o determinante principal nas decisões de tratamento ou se outros fatores também devem ser considerados.
Traduzido por IA · Ver original

The results of the HARMONi-6 trial raise important questions about our current understanding of biomarkers in NSCLC. We need to discuss whether PD-L1 TPS should be the primary determinant in treatment decisions or if other factors should also be considered.

Vote options for this statement: agree, disagree, or unsure
💬 Ver discussão
Be first to respond
Vote to see results
CLAIM Publicado por will • Apr 11, 2026
Devemos explorar como os insights do ensaio HARMONi-6 podem ser integrados aos marcos de tratamento existentes para NSCLC escamoso. Isso inclui considerar como dados demográficos e características de saúde dos pacientes influenciam a eficácia do tratamento.
Traduzido por IA · Ver original

We should explore how the insights from the HARMONi-6 trial can be integrated into existing treatment frameworks for squamous NSCLC. This includes considering how patient demographics and health characteristics influence treatment effectiveness.

Vote options for this statement: agree, disagree, or unsure
💬 Ver discussão
Be first to respond
Vote to see results
CLAIM Publicado por will • Apr 11, 2026
Embora o ensaio HARMONi-6 mostre promessa, depender unicamente do TPS de PD-L1 para estratégias de tratamento poderia simplificar demais as complexidades do NSCLC escamoso. Devemos garantir que as diretrizes clínicas não favoreçam prematuramente um tratamento em relação a outro, pois as respostas individuais dos pacientes podem variar amplamente.
Traduzido por IA · Ver original

While the HARMONi-6 trial shows promise, relying solely on PD-L1 TPS for treatment strategies could oversimplify the complexities of squamous NSCLC. We must ensure that clinical guidelines do not prematurely favor one treatment over another, as individual patient responses can vary widely.

Vote options for this statement: agree, disagree, or unsure
💬 Ver discussão
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us